Follow the 네이처셀 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 네이처셀 has published 42 insider filings. Market capitalisation: €1,556.1bn. The latest transaction was filed on 27 March 2026 (Purchase). Among the most active insiders: 라정찬. All data is openly available.
42
Insider Decl.
n/a
Thresholds
€1m
14 ops.
Buy Volume
n/a
4 ops.
Sell Volume
30Σ signal
Buys €1mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,649 of 27,687 companies
34.9
score / 100
Value
32
Quality
38
FCF yld-1.1%
Earn yld-0.2%
EV/EBITDA·
ROE·
Gross mgn46%
Net mgn-14%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
네이처셀 is a company in the health and pharmaceutical sector, listed on the XKRX exchange. It focuses on the development of cell therapies and biopharmaceutical products.